Evidence map›Paper›PMID 27993998›Full record

ArticleJournal of Crohn's & colitis2017

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

Ling Liu, Ying Dong, Mei Ye, Shi Jin, Jianbo Yang, Maria E Joosse, Yu Sun, Jennifer Zhang, Mark Lazarev, Steven R Brant and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 2 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Oridonin-Loaded PDA@Gel@GO Nanocapsules Modulate NLRP3 and Epithelial Repair in Colitis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. mBio · 2025
    Article
  18. Article
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Ling LiuDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ying DongDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mei YeDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shi JinDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jianbo YangDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Maria E JoosseDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yu SunDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jennifer ZhangDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mark LazarevDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven R BrantDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bashar SafarDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael MarohnDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Esteban MezeyDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xuhang LiDivision of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USSichuan University · CN

Funding

Translational Research Enhancement CoreP30DK089502 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ZACHOS, NICHOLAS CONSTANTINE · 2011 to 2020
$12.0M
NIDDK NIH HHS P30 DK089502
6 · The paper itself

Abstract

BACKGROUND AND

aimsNLRP3 inflammasome is known to be involved in inflammatory bowel diseases. However, it is controversial whether it is pathogenic or beneficial. This study evaluated the roles of NLRP3 inflammasome in the pathogenesis of inflammatory bowel disease in IL-10-/- mice and humans.

methodsNLRP3 inflammasome in colonic mucosa, macrophages, and colonic epithelial cells were analysed by western blotting. The NLRP3 inflammasome components were studied by sucrose density gradient fractionation, chemical cross-linking, and co-immunoprecipitation. The role of NLPR3 inflammasome in the pathogenesis of colitis was extensively evaluated in IL-10-/- mice, using a specific NLPR3 inflammasome inhibitor glyburide.

resultsNLRP3 inflammasome was upregulated in colonic mucosa of both IL-10-/- mice and Crohn's patients. NLRP3 inflammasome activity in IL-10-/- mice was elevated prior to colitis onset; it progressively increased as disease worsened and peaked as macroscopic disease emerged. NLRP3 inflammasome was found in both intestinal epithelial cells and colonic macrophages, as a large complex with a molecular weight of ≥ 360 kDa in size. In the absence of IL-10, NLRP3 inflammasome was spontaneously active and more robustly responsive when activated by LPS and nigericin. Glyburide markedly suppressed NLRP3 inflammasome expression/activation in IL-10-/- mice, leading to not only alleviation of ongoing colitis but also prevention/delay of disease onset. Glyburide also effectively inhibited the release of proinflammatory cytokines/chemokines by mucosal explants from Crohn's patients.

conclusionsAbnormal activation of NLRP3 inflammasome plays a major pathogenic role in the development of chronic colitis in IL-10-/- mice and humans. Glyburide, an FDA-approved drug, may have great potential in the management of inflammatory bowel diseases.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAnti-Bacterial AgentsApoptosis Regulatory ProteinsCARD Signaling Adaptor ProteinsCaspase 1Colitis, MicroscopicColonCrohn DiseaseCytokinesEpithelial CellsGlyburideHumansHypoglycemic AgentsInflammasomesInterleukin-10Adaptor Proteins, Signal TransducingAnti-Bacterial AgentsApoptosis Regulatory ProteinsCARD Signaling Adaptor ProteinsCaspase 1CytokinesGlyburideHypoglycemic AgentsIL10 protein, mouseInflammasomesInterleukin-10LipopolysaccharidesNALP1 protein, mouseNigericinNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanNlrp3 protein, mouseNod-like receptor pyrin domain-containing protein 6, mousePycard protein, mouseReceptors, Cell SurfaceIL-10inflammatory bowel diseases [IBD]NLRP3 inflammasome

Identifiers

PMID27993998
PMCPMC5881697
OpenAlexW2562786167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.